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A well-functioning hematopoietic system requires a certain robustness and flexibility to 
maintain appropriate quantities of functional mature blood cells, such as red blood cells 
and platelets. This review focuses on the cytokine receptor that plays a significant role in 
thrombopoiesis: the receptor for thrombopoietin (TPO-R; also known as MPL). Here, we 
survey the work to date to understand how this receptor functions at a molecular level 
throughout its lifecycle, from traffic to the cell surface, dimerization and binding cognate 
cytokine via its extracellular domain, through to its subsequent activation of associated 
Janus kinases and initiation of downstream signaling pathways, as well as the regu-
lation of these processes. Atomic level resolution structures of TPO-R have remained 
elusive. The identification of disease-causing mutations in the receptor has, however, 
offered some insight into structure and function relationships, as has artificial means of 
receptor activation, through TPO mimetics, transmembrane-targeting receptor agonists, 
and engineering in dimerization domains. More recently, a novel activation mechanism 
was identified whereby mutated forms of calreticulin form complexes with TPO-R via its 
extracellular N-glycosylated domain. Such complexes traffic pathologically in the cell and 
persistently activate JAK2, downstream signal transducers and activators of transcrip-
tion (STATs), and other pathways. This pathologic TPO-R activation is associated with a 
large fraction of human myeloproliferative neoplasms.
Keywords: thrombopoietin, thrombopoietin receptor, JAK2, calreticulin, N-glycosylation, myeloproliferative 
neoplasms, megakaryocytes, congenital amegakaryocytic thrombocytopenia
iNTRODUCTiON
The cytokine thrombopoietin (TPO) is the chief regulator of megakaryocyte (MK) and platelet 
production, signaling via its receptor, MPL (TPO-R). The receptor was first identified in 1992 (1) 
and its ligand, TPO, was cloned not long after by several independent groups (2–7). Since then much 
effort has been made to characterize TPO-R and understand its function in normal and pathological 
hematopoiesis.
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Thrombopoietin acts by binding to the extracellular portion 
of partially predimerized cell surface TPO-R, thought to cause 
a change in the receptor dimer arrangement and/or monomer–
dimer equilibrium, which initiates a cascade of signaling events 
within the target cell. TPO-R has no intrinsic kinase activity and 
utilizes the Janus kinase (JAK) family of proteins to transduce 
signal from the extracellular cytokine to the nucleus within the 
cell. Two JAKs, JAK2 and TYK2, constitutively associate with 
the cytoplasmic tail of TPO-R and are phosphorylated upon 
TPO signaling (8–10), although TYK2 does not seem to be 
essential in this pathway (11, 12). These activated JAKs then 
phosphorylate the receptor itself, as well as signal transducer 
and activator of transcription (STAT) 1, 3, and 5 (13–15), and 
additionally can activate the mitogen-activated protein kinase 
(MAPK) (16) and phosphatidylinositol-3 kinase (PI3K) path-
ways (17).
TPO-R is expressed predominantly on the surface of MKs, 
platelets, hemangioblasts, and hematopoietic stem cells (HSCs) 
(18, 19). This pattern of expression is indicative of the two key 
functions of TPO: the regulation of platelet production (20–22) 
and the maintenance of HSCs (20, 23, 24). These important and 
non-redundant effects of TPO can be seen in mice where either 
Tpo or Mpl have been genetically deleted. A dramatic reduction 
in platelet and MK numbers—to about 10% of that of wild-type 
mice—can be observed in these mice, while mature blood cells 
are not affected in other lineages. Mpl−/− mice additionally have an 
increase in circulating Tpo (20, 22), but otherwise all these mice 
are healthy and viable. In humans, however, a lack of functional 
MPL results in congenital amegakaryocytic thrombocytopenia 
(CAMT), a rare condition in which infants develop a platelet 
and MK deficiency that, untreated, leads to multilineage failure 
(25–27). This difference between the two species in fundamental 
requirement for MPL for sustainable hematopoiesis suggests that 
perhaps compensatory mechanisms exist in mice, which are not 
present in humans. Some reduction in myeloid cells in Mpl−/− 
mice as they age (23), however, does bring up the possibility that 
the lifespan of mice is too short to observe a complete exhaustion 
of HSCs.
While a complete loss of TPO-R leads to thrombocytope-
nia, other mutations in MPL have been identified in patients 
with increased platelet numbers, in disorders such as familial 
thrombocytosis and two of the myeloproliferative neoplasms 
(MPNs), essential thrombocythemia (ET), and myelofibrosis 
(MF) (28–35). Understanding physiological functions of TPO-R 
and how this is altered in disease is therefore clearly desirable to 
develop effective therapeutics to treat such conditions.
DOMAiN STRUCTURe
TPO-R is 635 amino acids in length and has three functional 
domains: an extracellular portion involved in cytokine binding, 
a transmembrane domain (TMD), and a cytoplasmic domain, 
likely largely unstructured, which binds JAKs and other signaling 
molecules, such as STATs (Figure 1C, upper panel). Membrane 
proteins are notoriously difficult to crystallize, and TPO-R is no 
exception. Consequently, much of our idea of TPO-R’s structure 
is based on studies of related cytokine receptors for which some 
parts of their structures are known, such as erythropoietin recep-
tor (EPO-R) and growth hormone receptor (GH-R).
eCD: THe SeNSOR
The extracellular domain (ECD) of the receptor is thought to 
follow a similar arrangement as the EPO-R and related receptors, 
except that it is composed of two adjacent pairs of fibronectin-
III (FNIII)-like domains rather than the single pair of EPO-R 
(Figure 1). Each FNIII-like domain consists of a series of seven 
antiparallel β-strands that stack in a β-sandwich. By homology 
with known related structures, the hinge region connecting 
the FNIII-like domains within a pair [also known as a cytokine 
receptor module (CRM)] forms the interface for cytokine bind-
ing (37). Several studies have indicated that the membrane distal 
CRM (CRM-1) is essential for interaction with TPO (38), since 
its deletion (or replacement with the membrane proximal pair) 
abrogates TPO binding and possibly has a role in preventing 
signaling in the absence of TPO (39).
Indeed, most of the ECD of murine TPO-R (Tpo-R) is missing 
in the murine myeloproliferative leukemia virus envelope protein 
(v-mpl), which, as its name suggests, drives a myeloproliferative 
leukemia in mice via an activated truncated form of TPO-R. 
This oncoprotein is a fusion of 100 amino acids derived from 
the Friend murine leukemia virus envelope sequence and a 184 
amino acid portion of Tpo-R (residues 440–623), comprising the 
transmembrane and cytoplasmic regions of the receptor, but lack-
ing N-terminal region of the receptor, including the membrane 
distal CRM, and most of the membrane proximal CRM (CRM-2) 
(40). It is unclear, however, whether it is the absence of CRM-1 
or the presence of a portion of the Friend murine leukemia virus, 
or a combination of the two, that brings about dimerization and 
activation of the truncated Tpo-R.
The ECD mutation F104S, located in the membrane distal 
FNIII-like domain of CRM-1, is found in CAMT patients, and 
studies of this mutant receptor in BaF3 cells suggest that an 
essential ligand-binding site is disrupted, as cells are neither 
stimulated by TPO nor internalize the cytokine (41), despite the 
presence of the receptor on the cell surface. The loss of ligand 
binding on mutagenesis of TPO-R F45, L103, and P257 indicates 
that these residues as well, predicted to be located within loops 
that form a hinge region, are likely to contribute to TPO binding 
(42). However, direct evidence via an experimentally derived 
structure of TPO-R in complex with TPO is necessary to validate 
this result.
TMD: THe CONTROL CeNTeR
The TMD is a helical section of the receptor that anchors it to 
the cell surface. Receptor dimerization is necessary for recep-
tor activation, and the role of the TMD in activation has been 
highlighted by the identification of activating mutations in this 
domain and the adjacent juxtamembrane region, as well as by 
biochemical studies of the dimerized transmembrane and cyto-
plasmic domain orientation.
A mutation at the juxtamembrane W515 residue was first 
identified as activating in cell lines by Staerk and colleagues (43) 
FiGURe 1 | Mechanisms of TPO-R activation. Upper panel: (A) the human TPO-R has common cytokine receptor features, such as pairs of cysteines and 
conserved motifs in the extracellular domain (ECD), and also contains unique properties that prevent its self-activation and make it exist as a monomer or 
monomer–dimer equilibrium. The membrane distal ECD, the H499 in the transmembrane domain (TMD), and the RW515QFP motif (orange) play important roles in 
maintaining the receptor inactive in the absence of ligand. H499 creates a break in the helical extracellular juxtamembrane and the TMD, regulating dimerization and 
preventing oncogenic activation by mutants that are found active in other species. W515 anchors the TMD in the membrane, tilts the TMD relative to the bilayer 
structure, and is oriented outside the dimer interface in the inactive orientation, W515 “out,” H499 “in”; activation will result in the opposite orientation: W515 “in,” 
H499 “out.” (B) The inactive dimeric state of the TPO-R (less energetically favored compared to monomer) exhibits helical structure that is restored above H499 and 
adopts the H499 “in” and W515 “out” with respect to the interface of more parallel TMD dimers. (C) TPO, TPO analogs such as romiplostim, small molecule TPO 
agonists, such as eltrombopag, and some activating mutations such as W515L or S505N found in MPNs are able to shift the equilibrium from this unique inactive 
dimer toward active dimers, where W515 is rotated more in the interface (“in”) and H499 is maintained more outside (“out”). TPO-R active dimers lead to positioning 
of JAK2 proteins in a conformation conducive for activation, transphosphorylation, and subsequent phosphorylation of tyrosine residues that are located in the 
cytoplasmic tail of the receptor and in JAK2 itself. The TPO-R F104S mutation results in receptor that is unable to bind TPO, therefore, this mutant receptor cannot 
be activated by TPO. Other mutations such as K39N or P106L produce a low level of TPO-R cell surface localization that is sufficient for signaling, but that does not 
efficiently clear TPO from circulation. (D) Replacement of the ECD and fusion of an artificial dimeric structure (coiled-coil domain of the Put3 transcription factor) to 
progressively shorter TMDs impose individually all seven possible dimeric orientations of the TPO-R TMD. The sequence depicted vertically is the C-terminus of the 
Put3 coiled-coil domain that is fused to different residues of the TMD to create dimers adopting different interfaces and probe function of each such interface (36). 
Lower panel: cartoons representing the helical TMD monomeric conformation depicted in (A) and the helical TM dimer orientations in (B) (His “in”) and in (C) (His 
“out”). Conserved Box1, Box2, and tyrosine residues are shown for the cytosolic domain of TPO-R in (C).
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(W515A mutation) and by Pikman and colleagues (29) in patients 
with acquired ET and MF (W515L mutation). While mutations 
of this residue to lysine and leucine are the most prevalent in 
patients, extensive mutagenesis of this residue has further 
demonstrated that all residues (except tryptophan, cysteine, 
and proline) constitutively activate the receptor when placed at 
this position (44). W515 has a key role in preventing activation 
in the absence of cytokine binding. This residue is part of the 
amphipathic helical motif RWQFP, which is directly adjacent to 
the C-terminal end of the TMD (Figure 1A, lower panel). This 
motif is unique to TPO-R, and its deletion or mutation activates 
the receptor in the absence of ligand (43). NMR studies of trans-
membrane peptides indicate that mutation of W515 decreases the 
tilt angle relative to the lipid bilayer normal, bringing the dimer 
into an active conformation (45).
Another clinically relevant TMD mutation, which activates 
TPO-R is S505N, and is found in patients with hereditary and 
rare sporadic cases of thrombocythemia. This mutation was first 
reported in a Japanese family (28) and was later found with some 
frequency in Italian patients with the same disorder (46, 47). S505N 
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induces stable active receptor dimers (28), and mutational studies 
show that H499 near the N-terminus of the human TPO-R TM 
domain is protective against the constitutive activation driven by 
several other asparagine mutations that fully activate the murine 
receptor (48). The first NMR studies on the transmembrane 
helix of TPO-R found that its helical region is not continuous 
but rather unexpectedly contains several non-helical residues in 
the sequence preceding H499 in the human form of the recep-
tor (Figure  1A, lower panel), although the same region in the 
murine receptor is helical (49). Both the S505N mutation and 
the TPO-R small molecule agonist eltrombopag, which binds to 
H499 (Figure 1C, upper panel), however, induce helical structure 
into the region, stronger dimerization, and receptor activation, 
although eltrombopag is not effective on the murine receptor as 
it lacks H499 (48).
Studies of forced dimerization at different orientations of the 
TMD (50, 51) indicate that cytokine-induced dimerization is not 
simply a binary on/off switch in the case of TPO-R, but rather 
there are a number of possible “active” outputs.
These studies of intracellular domain orientation of TPO-R, 
similar to those performed earlier of EPO-R (36), suggest that 
the geometry of these regions play a key role in deciding both 
the quality and the quantity of the resulting signal (50, 51). One 
approach has been to use a coiled-coil dimerization domain that 
is derived from the yeast transcription factor Put3 and fused to 
the intracellular domain of Tpo-R (Figure 1D, upper panel) (51). 
These fusion products are therefore forced to dimerize constitu-
tively and do not require ligand to activate downstream signaling 
pathways. Different orientations of the two intracellular domain 
chains could then be systematically altered with the progressive 
deletions in the juxtamembrane region, which would be pre-
dicted to induce rotation within the receptor dimer. In this way, 
the seven possible relative orientations of the transmembrane and 
cytoplasmic domains could be imposed. Unlike EPO-R, where 
these experiments found essentially only a single symmetrical 
dimeric orientation that was able to signal, TPO-R had several 
conformations that supported cell proliferation, with differing 
signaling output and biological effects, including cell–cell adhe-
sion and MK differentiation.
The concept that rotations of the dimeric receptor TMDs 
drive TPO-R activation, rather than dimerization alone, is 
supported by other independent approaches, such as TOXCAT 
(ToxR-mediated activation of chloramphenicol acetyltransferase 
reporter assay) and cysteine cross-linking assays (50). From 
these results, the authors propose three different interfaces in the 
TPO-R TMD dimer: one active, one inactive, and one intermedi-
ate activity.
CYTOPLASMiC DOMAiN: THe 
TRANSMiTTeR
The portion of TPO-R that extends into the cytoplasm is the 
region of the receptor which binds JAKs, as well as interacting 
with other intracellular proteins, notably signal transducers, such 
as STATs. The receptor has five cytoplasmic tyrosine residues 
that, when phosphorylated, serve as potential docking sites for 
SH2-domain-containing proteins, including STATs and LNK. 
Accordingly, several studies have attempted to determine a func-
tion for each of these five sites [Y521, Y542, Y591, Y626, and Y631; 
also referred to as Y7, Y28, Y77 (78 in mouse), Y112, and Y117, 
numbered with respect to the cytoplasmic domain alone] and 
identify proteins interacting with these phosphorylated tyrosines.
Y521 and Y591 have been implicated in the negative regulation 
of TPO signaling (52), the former as part of a lysosomal targeting 
motif, and the latter via an interaction with adaptor protein AP2, 
which mediates receptor internalization through recruitment of 
clathrin (53). Aside from this lysosomal degradation, activated 
TPO-R is also subject to degradation by the proteasome, undergo-
ing ubiquitination via the E3 ubiquitin ligase CBL, which targets 
the receptor on the cytoplasmic residues K553 and K573 (54).
In contrast to most other cytokine receptor superfamily mem-
bers that exhibit short half-lives, TPO-R is long-lived both at the 
cell surface and in intracellular stores (55). Its traffic to the cell 
surface and stability is promoted by JAK2 (55). A consequence 
of this prolonged half-life is observed in its ability to be recycled 
(56). Surface biotinylation studies have shown that reappearance 
of cell surface TPO-R after internalization is due to recycling of 
the internalized receptor (56) and not transport of stored recep-
tor in intracellular pools (57). This recycling process is blocked 
in cells that coexpress TPO-R and JAK2 V617F, leading to cell 
surface TPO-R downmodulation (57).
The membrane distal tyrosines Y626 and Y631 (also denoted 
cytoplasmic residues Y112 and Y117) function as positive regula-
tory sites (52). The murine homolog of Y626 is required for cel-
lular differentiation and the phosphorylation of Shc, the adaptor 
that links receptor activation to the MAPK pathway (58). Y626 
additionally is necessary for the constitutive signaling in MPN 
driven by the mutation W515A (59).
Although the cytoplasmic domains of cytokine receptors show 
little sequence similarity, they do share two conserved elements, 
Box1 and Box2 (60). These motifs are involved in binding to JAKs 
and signal transduction (61, 62). Box1 is essential for JAK bind-
ing and activation, and this motif centers on two evenly spaced 
proline residues (PXXP). Upstream from the Box1 sequence, 
many cytokine receptors possess conserved hydrophobic residues 
at positions −1, −2, and −6 (63). These residues form a “switch 
motif,” which is required for cytokine-induced JAK2 activation 
but not for JAK2 binding (63, 64). Located downstream from 
Box1, Box2 is less well defined by an increased serine and glutamic 
acid content, along with hydrophobic residues, and its presence is 
not always necessary for a proliferative signal (61, 65, 66).
The cytoplasmic region of TPO-R, just as for other cytokine 
receptors, is considered to lack in large part secondary structure, 
especially around tyrosines that are phosphorylated, and this 
flexibility likely accounts for its imperviousness to crystallization 
attempts. As a consequence, these motifs have, until recently, only 
been defined indirectly through mutagenesis studies. However 
in the last few years, clever strategies first used by the Lupardus 
group to cocrystallize cytokine receptor cytoplasmic regions 
with FERM and SH2 domains of JAKs, either as a fusion protein 
or as distinct entities, have proven to be effective. To date, the 
structures of a section of the cytoplasmic domain of IFNAR1 
(PDB 4PO6) (67), IFNLR1 (PDB 5IXD; 5L04) (68, 69), and an 
IFNLR1:IL10RA chimera (PDB 5IXI) (68), together with their 
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cognate JAKs (TYK2 for IFNAR1 and JAK1 for IFNLR1 and 
IL10R) have been determined. These first snapshots allow us to 
visualize the structural basis of the interaction between cytokine 
receptors and their JAKs and give context to the box motifs.
It had previously been assumed that the JAK FERM domain 
alone participated in receptor binding (70–72), although studies 
of JAK1 and gp130 implicated the SH2 as well (73). The structural 
data, however, when taken together, show Box1 binds to the FERM 
domain, while Box2 interestingly binds to the SH2-like domain of 
TYK2, in a manner reminiscent of a phosphotyrosine peptide to 
a classical SH2 domain (67). Whether a similar binding mode is 
used by TPO-R is yet to be seen, as those structures concern type 
II cytokine receptors, while TPO-R is a type I cytokine receptor. 
Indeed, one might speculate that variations in binding sites and 
their respective affinities determine the specificity of particular 
cytokine receptors for particular JAKs.
How TPO-R interacts with JAK2 is particularly relevant in the 
context of disease driven by mutations in JAK2, specifically JAK2 
V617F, which occurs in about half of patients with ET and MF, 
and most patients with polycythemia vera (34, 74–77). These three 
diseases are collectively known as MPNs, and in in vitro (78), as 
well as in a transgenic JAK2 V617F mouse model of MPN (79), 
the disease phenotype is dependent on the expression of TPO-R. 
Although the cell surface expression of TPO-R is downregulated 
in the presence of JAK2 V617F, as discussed above, there is suf-
ficient receptor to allow constitutive activation.
This suggests TPO-R could be a good therapeutic target for 
the treatment of MPN, either by interfering with its interaction 
with JAK2 V617F or through suppression of TPO-R expression. 
In addition to these two approaches, a TPO-R antagonist has also 
recently been studied as a therapeutic for MF (80), exploiting the 
requirement of TPO-R expression in HSCs for maintaining a 
reservoir of HSCs and preventing exhaustion (81).
A detailed understanding of the TPO-R and JAK2 complex 
and the specificity of this particular cytokine receptor for this 
particular JAK is likely to be useful in determining a strategy to 
curb pathological signaling via JAK2 V617F while minimizing 
off-target effects. Modifying TPO-R expression, on the other 
hand, could be problematic, due to its role in regulating TPO 
levels.
TPO-R eXPReSSiON AND TPO 
ReGULATiON
The constitutive production of TPO occurs primarily in the liver, 
while the kidneys contribute to a lesser extent (82). Old desia-
lylated platelets bind to the Ashwell–Morell receptor and promote 
TPO mRNA production (83) (Figure 2). Hepatocytes can also be 
induced to produce TPO by IL-6 stimulation (84), which likely 
accounts for the thrombocytosis seen in patients with chronic 
inflammatory diseases, such as rheumatoid arthritis and ulcera-
tive colitis. However, unlike EPO, TPO levels are for the most part 
not regulated by changes in gene expression, but rather TPO is 
taken out of circulation through binding to its receptor and being 
internalized and degraded (85, 86). Platelets and MKs display the 
bulk of TPO-R expressed, and so their numbers largely regulate 
TPO levels (86, 87). While TPO-R expression in mice is dispen-
sable for thrombopoiesis, its expression on MKs and platelets is 
essential to prevent an excessive production of MKs and other 
myeloid cells (88). MKs and platelets thus act as a sink via the 
TPO-R, restricting the availability of circulating TPO that could 
stimulate their production from the pool of progenitor cells.
In thrombocytopenia, there is an insufficient platelet mass 
to remove TPO from circulation, resulting in high plasma TPO. 
This feedback mechanism means low platelet numbers result in 
high levels of TPO, which then stimulates the production of MKs 
and platelets. Consequently, in the case of Mpl−/− mice, where 
Tpo-R is genetically deleted, high levels of circulating TPO are 
observed (22). Similarly in humans where TPO-R loss of func-
tion causes low platelet levels, high serum TPO accompanies the 
thrombocytopenia.
This direct regulatory role of platelets, and more specifically 
TPO-R-binding, on serum TPO levels and production has 
unexpected consequences: a partial loss of receptor function 
can counterintuitively result in an increase in platelet numbers. 
MPL Baltimore (MPL K39N) was the first identified example of 
this phenomenon, a mutation identified in three thrombocytosis 
patients. Further investigation found MPL K39N in approxi-
mately 7% of African-American populations tested and not at 
in all populations of European-, Asian-, or Hispanic-American 
identity (32). Subsequent cases have also been reported in an 
Afro-Caribbean family in the UK (89), an Ethiopian Jewish boy 
in Israel (90), and a French woman born in northern Africa (91), 
suggesting this gene exists in other populations of African origin.
Residue K39 is located in the ECD of TPO-R, and although 
the structural effect this mutation brings about is not clear, the 
outcome is reduced protein expression and cell surface localiza-
tion, observed in both patient platelets and a murine cell line. 
Another extracellular TPO-R mutation, P106L, is similarly found 
at a low frequency within a specific population, in this case Arabs 
(33) and leads to a hereditary thrombocytosis. We and others 
have sought to determine the mechanisms underlying this latter 
disease (92, 93).
The Stockklausner study was not able to detect TPO-R P106L 
on the surface of cells, and therefore put forward a rather unlikely 
model of TPO internalization not mediated by binding to its 
receptor on the cell surface, together with TPO-R P106L hyper-
sensitivity to this internalized TPO (92). Nonetheless, we were 
able to detect TPO-R P106L on the surface of cells using several 
techniques, and so our conclusions differed from the earlier study 
(93). Our results indicated that this mutation led to a trafficking 
defect such that there was low, but detectable, expression of the 
receptor on the cell surface. This low level of expression is suf-
ficient for signal transduction but not enough for TPO clearance, 
ultimately resulting in thrombocytosis in patients and in a mouse 
model.
A similar paradoxical thrombocytosis as a consequence of 
subnormal receptor expression was previously observed in an 
attempt to use gene therapy to correct the thrombocytopenia 
caused by the absence of functional TPO-R at the surface of 
hematopoietic cells. Lannutti and colleagues unexpectedly 
found that expressing TPO-R at lower than normal physiological 
levels in Mpl−/− mice led to elevated plasma TPO levels, driving 
FiGURe 2 | Thrombopoietin (TPO) production, function, and homeostasis. TPO is mainly produced by liver parenchymal cells and by endothelial cells of the 
liver sinusoids. TPO production can also occur in proximal tubule cells of the kidney and in bone marrow stromal cells. The production is mainly constitutive (with no 
change in TPO mRNA levels), and regulation is mediated by negative feedback of the TPO-R-expressing platelet pool that internalizes and destroys free circulating 
TPO. IL-6 is able to induce hepatic TPO mRNA production in reactive/inflammatory thrombocythemia. Binding of old desialylated platelets to the hepatic Ashwell–
Morell receptor (AMR) has been shown to promote liver TPO mRNA production. TPO plays a dual role in hematopoiesis, with an inhibiting role (red arrow) that 
occurs at the two extremes of the hematopoietic process, keeping stem cells quiescent and promoting a cell cycle arrest in late megakaryocytes (MKs), and a 
positive role in stimulating immature precursors (CMP and MEP) and promoting growth of very early progenitors of megakaryopoeisis (BFU-MK and CFU-MK).
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excessive megakaryopoiesis and thrombocytosis (94). A similar 
finding of thrombocytosis has also been described for Mpl−/− 
mice, where the expression of a Mpl transgene was lower than 
physiological levels in mature MKs and platelets (95). Levels of 
receptor on the cell surface are therefore a key element in the 
regulation of TPO-R signaling, and so its traffic and plasma 
membrane localization must be carefully regulated for normal 
hematopoiesis.
Mechanistically, paradoxical thrombocytosis can occur 
when TPO-R is expressed at low levels in late MKs and platelets, 
due to increased TPO concentrations in plasma that will be 
able to activate even low levels of TPO-R on early progenitors, 
such as megakaryoblasts. The basis for this phenomenon is 
that the amount of activated receptors required for signaling 
in early progenitors is much smaller than for ligand uptake and 
degradation (93).
TPO-R TRAFFiC TO THe CeLL 
MeMBRANe
It is not fully understood how the trafficking of TPO-R to the 
cell surface is regulated, although JAK2 and TYK2 are known 
to promote localization at the cell membrane and stability of the 
receptor (55). The chaperone effect of JAK2 and TYK2 depends 
on their N-terminal FERM domains. In complexes with JAK2 or 
TYK2, the TPO-R cytosolic domain probably masks degradation 
signals, and the EndoH-resistant mature form accumulates. 
Interestingly, the cell surface TPO-R pool appears to be even 
more stable than the intracellular pool (55). TPO-R expression 
is altered in MPNs, as shown by the downregulation of TPO-R in 
platelets and megakaryoctes of MPN patients, first described in a 
classic study from the Spivak laboratory (96). Moreover, TPO-R 
downmodulation has since been observed to occur in many 
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MPN patients, irrespective of driver mutation (96–99). Further, 
the cell surface and intracellular levels of TPO-R are decreased 
by the MPN mutant JAK2 V617F, which inhibits recycling and 
promotes proteasomal degradation of TPO-R (57).
TPO-R is an N-glycosylated protein and contains four puta-
tive N-glycosylation sites in its ECD. The role of N-glycosylation 
for cytokine receptor traffic and ligand binding does appear to 
vary across receptors (100–104), but for TPO-R the data suggest 
that cell surface expression of TPO-R is regulated by the use of 
a combination of N-glycosylation sites, and that the receptor 
is able to respond to TPO, once it is localized at the plasma 
membrane (105).
A NOveL MeCHANiSM OF TPO-R 
TRAFFiC AND ACTivATiON: COMPLeX 
FORMATiON wiTH CALReTiCULiN (CALR) 
MUTANTS iN MPN
The trafficking of TPO-R and how this can be altered in disease 
has become particularly topical since the discovery that the 
majority of MPN cases of ET and MF where MPL or JAK2 is not 
mutated harbor mutations in the gene for the endoplasmic reticu-
lum (ER) chaperone CALR. CALR is a soluble protein that acts as 
a calcium buffer in the ER, binding calcium ions via its negatively 
charged C-terminal end. CALR also has an essential role in the 
ER’s protein quality control system as a chaperone, binding to 
the glycans of nascent N-glycosylated proteins, retaining these 
glycoproteins within the ER until properly folded (106).
These MPN-associated mutations result in the loss of CALR’s 
ER retention signal, and the generation of a novel C-terminal 
sequence due to recurrent +1 frameshifts (107, 108). These 
mutant CALRs can activate TPO-R in the absence of TPO ligand 
(98) (Figure 3). That CALR mutants induce JAK-STAT signaling 
by specifically activating TPO-R has been observed in several sys-
tems (98, 109–113), although the details of the specific structural 
mechanism of TPO-R activation remain to be determined and 
will require an atomic-level resolution structure of the complex. 
One possibility is that this mutant CALR fixes the TPO-R dimer 
in an orientation corresponding to one of the “active” inter-
faces observed in the coiled-coil fusion experiments described 
above (51).
Indeed, mutant CALRs induce close proximity (dimeriza-
tion) of the C-terminal JAK-homology 1 kinase domains of 
JAK2 via TPO-R, as determined by protein complementation 
assays (98, 109–112). Available evidence indicates that TPO-R 
activation depends on an interaction with CALR mutants that 
requires the N-glycosylation sites of the TPO-R ECD and both 
the lectin-binding domain and the new positively charged tail of 
CALR mutants (98, 109–112) (Figure 3). Experiments using an 
array of cytokine receptors (both type I and type II) show that 
the only cytokine receptor able to support constitutive signaling 
in the presence of CALR mutants is TPO-R. A weak activation, 
insufficient to promote long-term proliferation, is also detected 
with the granulocyte colony-stimulating factor receptor, and 
no activity with other closely related receptors such as EPO-R, 
GH-R, prolactin receptor, interleukin, or interferon receptors (98, 
109). Expression of CALR mutants in parental Ba/F3 or 32D cells 
leads to autonomous growth only upon expression of the Mpl 
gene, coding for Tpo-R (98, 109–113). Of note, coexpression with 
a soluble TPO-R ECD blocked activation of TPO-R by CALR 
mutants in a dose-dependent manner, providing the receptor 
was N-glycosylated (98). Detailed analyses further showed that 
of the four N-linked sugars, the main one mediating interactions 
with CALR mutants is N117, which is the most distal from the 
membrane (98).
Coimmunoprecipitation of total and cell surface proteins with 
CALR mutants demonstrates that they interact more strongly 
with TPO-R than wild-type CALR (98, 109–112), and that in 
the presence of CALR mutants, TPO-R is transported to the cell 
surface in an EndoH-sensitive immature form (98). Confocal 
immunofluorescence and cellular fractionation show that CALR 
mutants exit the ER and are located in a distinct pattern from that 
of wild-type CALR, mainly in the ER-to-Golgi vesicles and at the 
cell surface (98). In addition, CALR mutants appear to be much 
more unstable than the wild-type CALR (98, 109–112).
The consequence of persistent activation of TPO-R is activa-
tion of JAK2/STAT5/STAT3/STAT1 and also of the other JAK2-
dependent pathways, MAP-kinase/ERK and PI3K/AKT. While 
JAK2 and PI3K inhibitors synergize to inhibit proliferation of 
JAK2 V617F cells, in the case of CALR mutant transformed 
cells, JAK2 inhibitors synergized with ERK inhibitors, suggesting 
subtle differences in the levels of activated downstream pathways 
(98, 109–112). In vivo, expression of CALR mutants leads to 
pathologic MK proliferation, resulting in an ET phenotype, 
which can progress to MF (98, 109–112). While all pathogenic 
CALR mutants possess the +1 frameshift, small differences in the 
preceding sequence to the novel positively charged tail exist, and 
the class of mutants represented by del52, where less of the initial 
negative charges remain on the final protein, appear to signal 
more strongly and lead to a more pronounced myeloproliferation 
phenotype (98, 109–112).
The results obtained in cell lines transduced with retroviral 
vectors expressing CALR mutants were recently confirmed by cre-
ating endogenous heterozygous and homozygous CALR mutants 
using the CRISPR/Cas9 system (96–99, 109–112). Interestingly, 
in such cells it is observed that the cell surface levels of TPO-R 
are downmodulated and that while there is constitutive activity 
of TPO-R, response to TPO is slightly decreased, consistent with 
such downregulation (96–99).
Overall, this is a novel and fascinating mechanism of oncogen-
esis whereby a mutated chaperone transforms cells by persistently 
activating a specific cytokine receptor, namely TPO-R (Figure 3), 
fitting well with the involvement of CALR mutants in pathologic 
MK proliferation.
ReCePTOR AGONiSTS
Since the discovery of TPO as the ligand for MPL, there has been 
significant clinical interest in its use as a stimulator of platelet 
production. First-generation forms of TPO used in clinical trials 
were developed almost 20  years ago, primarily a recombinant 
human TPO and a PEGylated TPO-derived peptide (PEG-
rHuMGDF). Both of these treatments showed very positive effects 
FiGURe 3 | Myeloproliferative neoplasm (MPN)-associated calreticulin (CALR) mutants bind to TPO-R and activate JAK2 signaling in the absence of 
thrombopoietin (TPO) ligand. CALR mutants that result from one base pair shifts in the reading frame in exon 9 have a novel positively charged tail (*). These 
CALR mutants bind to the N-glycosylated extracellular domain of TPO-R, and such complexes in the secretory pathway and at the cell surface activate JAK2. This 
results in persistent activation of STAT5 (as shown here) and also STAT1, STAT3, mitogen-activated protein kinase (MAPK)/ERK and phosphatidylinositol-3 kinase 
(PI3K)/AKT pathways. Wild-type CALR (left), on the other hand, is retained in the endoplasmic reticulum, due to the presence of its KDEL sequence (lacking in 
MPN-associated mutant CALR) and does not activate TPO-R.
8
Varghese et al. TPO-R Traffic and Activation
Frontiers in Endocrinology | www.frontiersin.org March 2017 | Volume 8 | Article 59
(114, 115), increasing thrombopoiesis in both thrombocytopenic 
and healthy subjects. Despite these initially promising results, 
neither drug trial continued as some healthy subjects treated 
with PEG-rHuMGDF-developed thrombocytopenia due to the 
production of antibodies that cross-reacted with endogenous 
TPO (116, 117).
The development of second-generation thrombopoietic agents 
has accordingly aimed at minimizing structural similarities with 
TPO. These TPO-R agonists can be classified into three types: 
TPO peptide mimetics, TPO non-peptide mimetics, and TPO-R 
antibodies.
Two receptor agonists are currently licensed by the FDA and 
the EMA: romiplostim (AMG 531; Nplate, Amgen) and eltrom-
bopag (SB-497115; Revolade, GlaxoSmithKline). Romiplostim, 
a TPO peptide mimetic, was developed from a peptide library 
screen that identified a 14-amino acid peptide with no homology 
to TPO, yet high affinity for TPO-R and capable of stimulating a 
TPO-responsive cell line (118). Eltrombopag, on the other hand, 
does not bind the receptor in the same manner as TPO, but rather 
targets TPO-R’s TMD, or more specifically its extracellular jux-
tamembrane end. Its mechanism of action appears to derive from 
inducing helical secondary structure around the TMD residue 
H499, where it binds altering the positioning of the receptor 
dimer to an activating conformation that exhibits H499 stabilized 
outside the dimer interface (48).
Romiplostim and eltrombopag are licensed for the treatment 
of chronic immune thrombocytopenia and thrombocytopenias 
of liver diseases, such as hepatitis C infection, but another poten-
tial target for treatment with receptor agonists is CAMT. There 
are many different mutations in TPO-R that lead to CAMT, and 
apparently a number of ways for TPO-R function to fail. Several 
studies have sought to differentiate the various types of failure in 
the hope that this could define specific therapeutic strategies for 
individual patients, depending on the mutation they bear.
While nonsense and frameshift mutations can be assumed to 
produce truncated receptor, lacking essential domains for signal 
transduction, it is more difficult to predict the effect of missense 
mutations. We and others have sought to determine what sort 
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of function is altered by each particular mutation in TPO-R (41, 
42, 119). Most of these missense mutations identified in CAMT 
patients are found in the ECD of TPO-R, and from these stud-
ies, we can glean that for the most part these mutant receptors 
fail to signal due to lack of presentation on the cell surface (42). 
There appear to be several different defects that contribute to this 
outcome, including a failure to express at an mRNA level, reduced 
expression at a protein level, and improper N-glycosylation (119). 
Some CAMT TPO-R mutant proteins do nonetheless make it 
to the cell surface, and cells expressing these mutant receptors 
either do not respond or have a severely perturbed response to 
TPO stimulation (41, 42). A pertinent question is, then, are these 
receptors able to signal when treated with receptor agonists? And 
could CAMT patients with these particular mutations benefit 
from this type of therapy?
One study examined the effect of receptor-targeting agonists 
murine Amgen Megakaryopoiesis Protein 4 (m-AMP4; Amgen), 
a version of romiplostim effective on murine TPO-R, and LGD-
4665 (Ligand Pharmaceuticals), a small molecule non-peptide 
TPO-R agonist, effective on CAMT TPO-R mutant receptors (41). 
They found that cells expressing the CAMT mutant TPO-R F104S 
did not proliferate in the presence of TPO or the ECD targeting 
m-AMP4 but did respond to the transmembrane targeting LGD-
4665 small molecule. The results of this study demonstrate that 
these receptor agonists are not interchangeable, and knowledge of 
the mutation driving the disease could inform treatment choice. 
Despite promising early results, this latter drug nonetheless does 
not seem to have progressed to a phase III trial.
The third group of TPO-R agonists with potential in the clinic 
is receptor antibodies, including minibodies and diabodies. 
Minibodies are single-chain antibody fragment dimers, while 
diabodies are non-covalent dimers of two covalently linked anti-
body fragments. These alternative approaches involve identifying 
antibodies that activate receptor function. Orita and colleagues 
(120) produced two novel TPO-R agonists, one that had activity 
in a megakaryocytic cell line, as well as in vivo in cynomolgus 
monkeys, and a second which increased proliferation in TPO-
dependent cell lines expressing TPO-R with mutations found in 
CAMT patients. There is also interesting evidence from work on 
diabodies targeting the EPO-R ECD that these receptor agonists 
are able to induce different signaling responses, as a function 
of the distances of separation imposed on receptor monomers 
(121), suggesting this might also apply to TPO-R, given that 
several active dimer interfaces have been identified for the latter 
receptor (51).
ReCePTOR ANTAGONiSTS
Efforts to dampen, rather than activate, TPO signaling with 
antagonists of TPO-R have only recently been described (80). 
LCP4, a 20-amino acid cyclic peptide TPO-R antagonist, was 
used to treat CD34+ cells derived from splenic, peripheral blood, 
and bone marrow cells of MF patients. Although TPO promoted 
the proliferation and differentiation of these cells, LCP4 was 
able to inhibit these effects, more profoundly in cells from MF 
patients than healthy controls, effectively depleting MF HSCs 
and progenitor cells (80). This new class of drug has exciting 
potential to target HSCs bearing activating mutations, while 
sparing normal HSCs.
TPO-R AND ePO-R: SOMe 
COMPARiSONS
Belonging to the same homodimeric type I subfamily of cytokine 
receptors and activating the same JAK2 tyrosine kinase, TPO-R 
and EPO-R nonetheless exhibit significant differences in their 
induction, expression pattern, biology, mechanism of activa-
tion, and signaling. TPO-R is expressed on HSCs, early myeloid 
progenitors, and MK progenitors, as well as on the eventual 
differentiated platelets, while EPO-R is expressed on erythroid 
progenitors (but not beyond basophilic erythroblasts and not on 
mature red cells), on endothelial cells, and on neurons. TPO-R 
regulates platelet numbers that can increase by twofold to five-
fold in certain pathological conditions, while EPO-R regulates 
the hematocrit, which has a much smaller range of increase 
(above the normal values of 42–44%). EPO-R is predominantly a 
preformed dimer, at least in transfected or transduced cells (122, 
123), and its transmembrane sequence forms dimers with great 
efficiency (122, 124, 125), that is significantly higher than that of 
TPO-R TMDs (50). For the latter, preformed dimers have also 
been detected (45, 50), but overall the extent of predimerization 
appears lower and a monomer-dimer equilibrium might be 
operative in cells expressing physiological levels of TPO-R.
Activation of TPO-R has been reported by many mechanisms, 
including mutations in transmembrane and juxtamembrane 
domains, leading to disease-causing mutations (126). Also, 
artificially one can activate TPO-R quite easily, with antitag 
antibodies (127) or by small molecules (for example, eltrom-
bopag). In engineered constructs, it appears that several dimeric 
interfaces imposed on the TMD can lead to TPO-R activation 
(50, 51). This is not the case for EPO-R, which requires one 
specific interface for activation (36), and in which no activat-
ing transmembrane or juxtamembrane mutations have been 
reported in blood diseases. An exception is observed in acute 
lymphoblastic leukemia, where translocations of EPO-R with 
high expression levels have been recently described (128). 
Finally, an additional point of difference that has come to light 
is that mutated forms of CALR have been shown to specifically 
activate TPO-R but not EPO-R (98).
CONCLUSiON
Since its discovery over a quarter of a century ago, our under-
standing of how TPO-R functions has gradually improved. While 
attempts to develop a detailed structural model of the receptor 
based on direct experimental evidence has had limited success, 
it has been possible to exploit knowledge of related receptors 
for homology-based predictions, as well as utilizing indirect 
mutagenesis studies. Despite this lack of structural information, 
the receptor has been extensively characterized and two small 
molecule receptor-binding agonists have been developed and 
approved for use in the clinic. The production of diabodies to 
modulate TPO-R activity is a promising potential addition to the 
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currently available treatments. We are hopeful that the coming few 
years will bring further insight into TPO signaling, particularly 
from a structural viewpoint, which could inform more targeted 
approaches in the design of therapeutics to treat thrombocytosis 
and other hematological disorders driven by abnormal TPO 
signaling.
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